Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSEUS: SAR442168 vs placebo in primary progressive multiple sclerosis
jRCT2021200028Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of tolebrutinib in primary progressive multiple sclerosis (PPMS), sponsored by Sanofi. Primary endpoint: 6-month composite Confirmed Disability Progression (cCDP). Started Jan 2021; status: completed.
02
Drugs
tolebrutinib
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on jRCT2021200028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200028.